Delivery Order SPE2DB22D3009-SPE2DB24FAS61
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation, is a delivery order valued at $16,783.10 for the supply of ANDEXXA 200 MG VIALS. The contract is a firm fixed price award issued by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the U.S. Department of Defense. Amerisourcebergen Drug Corp is the prime contractor and this award is not associated with any set-aside designation....
- This federal contract award, valued at $44,342.46, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, through Delivery Order SPE2DB21FQ12R. The award is for the supply of ANDEXXA 200 MG VIALS, a specialty pharmaceutical product. Amerisourcebergen, a subsidiary of the parent company Cencora, Inc., holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $79,161.66 firm fixed-price delivery order is for the supply of ANDEXXA 200 MG VIALS. The contract has an ultimate completion date of November 18, 2022 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award, valued at $13,863.06, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ANDEXXA 200 MG VIALS, a specialized medical product, to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and...
- This contract award, valued at $4,933.72, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ANDEXXA 200 MG VIALS, a specialty medication. The award is a delivery order under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office Division for the delivery of 4564433758 ANDEXXA 200 MG VIALS. The contract has a firm fixed price ceiling value of $33,293.65 and a completion date of May 20, 2024. This is a delivery order contract type with no set-aside designation. AmerisourceBergen, a major pharmaceutical distribution company, has been awarded this order as part of its Indefinite Delivery...
- The U.S. federal government awarded a delivery order contract valued at $6,658.72 to Amerisourcebergen Drug Corp's Corporate Office Division. The contract, awarded by the Defense Logistics Agency (DLA) Troop Support Medical, is for the supply of ANDEXXA 200 MG VIALS, a pharmaceutical product. This contract is not set aside for any particular business type. Amerisourcebergen is a major pharmaceutical distributor that holds several Indefinite Delivery Contracts (IDCs) with federal agencies,...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,888.85, is for the delivery of 4566586927 ANDEXXA 200MG VIALS 4S. This is a Firm Fixed Price Delivery Order contract with a performance period through December 4, 2024. The contract is not designated with a set-aside requirement. AmerisourceBergen Drug Corp holds a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is for the delivery of ANDEXXA 200 MG VIALS, a pharmaceutical product, to be delivered by March 8, 2024. The contract is a firm fixed price delivery order with a potential value of $10,377.47. No set-aside designation was used for...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ANDEXXA 200MG VIALS 4S, a medical product, with a firm fixed price of $20,794.59 and a period of performance through May 29, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp is the prime contractor and holds a significant Indefinite Delivery Contract (IDC) with...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB24FAS61Delivery Order
This federal contract award, valued at $14,801.16, is a delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a for-profit pharmaceutical distribution company. The contract is for the supply of ANDEXXA 200 MG VIALS, a pharmaceutical product. The award is part of a larger indefinite delivery contract (IDC) between AmerisourceBergen Drug Corporation and DLA, valued at up to $999,999,999.00 and running through December 31, 2025. This IDC serves as the primary contract vehicle for AmerisourceBergen to deliver pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. The contract does not have a set-aside designation. AmerisourceBergen Drug Corporation is a subsidiary of the parent company Cencora, Inc., which does business as AmerisourceBergen.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.8k | 3/21/24 |